Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Hereditary chronic pancreatitis Rosendahl J; Bodeker H; Mossner J; Teich NOrphanet J Rare Dis 2007[Jan]; 2 (ä): 1Hereditary chronic pancreatitis (HCP) is a very rare form of early onset chronic pancreatitis. With the exception of the young age at diagnosis and a slower progression, the clinical course, morphological features and laboratory findings of HCP do not differ from those of patients with alcoholic chronic pancreatitis. As well, diagnostic criteria and treatment of HCP resemble that of chronic pancreatitis of other causes. The clinical presentation is highly variable and includes chronic abdominal pain, impairment of endocrine and exocrine pancreatic function, nausea and vomiting, maldigestion, diabetes, pseudocysts, bile duct and duodenal obstruction, and rarely pancreatic cancer. Fortunately, most patients have a mild disease. Mutations in the PRSS1 gene, encoding cationic trypsinogen, play a causative role in chronic pancreatitis. It has been shown that the PRSS1 mutations increase autocatalytic conversion of trypsinogen to active trypsin, and thus probably cause premature, intrapancreatic trypsinogen activation disturbing the intrapancreatic balance of proteases and their inhibitors. Other genes, such as the anionic trypsinogen (PRSS2), the serine protease inhibitor, Kazal type 1 (SPINK1) and the cystic fibrosis transmembrane conductance regulator (CFTR) have been found to be associated with chronic pancreatitis (idiopathic and hereditary) as well. Genetic testing should only be performed in carefully selected patients by direct DNA sequencing and antenatal diagnosis should not be encouraged. Treatment focuses on enzyme and nutritional supplementation, pain management, pancreatic diabetes, and local organ complications, such as pseudocysts, bile duct or duodenal obstruction. The disease course and prognosis of patients with HCP is unpredictable. Pancreatic cancer risk is elevated. Therefore, HCP patients should strongly avoid environmental risk factors for pancreatic cancer.|*Genetic Predisposition to Disease[MESH]|Adult[MESH]|Animals[MESH]|Carrier Proteins/genetics[MESH]|Child[MESH]|Cystic Fibrosis Transmembrane Conductance Regulator/genetics[MESH]|Cystic Fibrosis/diagnosis/genetics[MESH]|Databases, Genetic[MESH]|Diagnosis, Differential[MESH]|Disease Models, Animal[MESH]|Genetic Counseling/methods[MESH]|Genetic Testing/methods[MESH]|Humans[MESH]|Mice[MESH]|Mutation[MESH]|Pancreatic Neoplasms/genetics[MESH]|Pancreaticojejunostomy[MESH]|Pancreatitis, Chronic/complications/diagnosis/*genetics/therapy[MESH]|Prognosis[MESH]|Rats[MESH]|Risk Factors[MESH]|Trypsin Inhibitor, Kazal Pancreatic[MESH]|Trypsin/genetics[MESH]|Trypsinogen/genetics[MESH] |